From Frequent Management to Long-Acting Treatment: How Plozasiran's Three-Month Dosing Is Changing FCS Care

Discover how Plozasiran, the world's first APOC3 siRNA therapy, is transforming Familial Chylomicronemia Syndrome (FCS) management with just one injection every three months.

Top Stories

Is Head and Neck Cancer Hereditary? A Comprehensive Guide to Genetics, Risk Factors, and Prevention Strategies

China's First Generic Tiotropium Bromide and Olodaterol Inhalation Spray Approved: Ending an 8-Year Market Exclusivity and Bringing New Options for COPD Treatment

Latest Coverage

How Effective Is Afatinib for Head and Neck Cancer? Indications, Clinical Efficacy, and Safety Overview
How Effective Is Afatinib for Head and Neck Cancer?

HER2 ADCs for Brain Metastases: Global Leading Therapies and Clinical Advances
In recent years, antibody-drug conjugates (ADCs) have rapidly transformed the treatment landscape for HER2-positive s...

Will Bispecific Antibodies Transform the Treatment of Head and Neck Cancer? An Overview of the Latest Research and Clinical Advances
In recent years, bispecific antibodies (BsAbs) have emerged as one of the most promising innovations in cancer immuno...

Why Can CAR-T Therapy Cost Tens or Even Hundreds of Thousands More, Even for the Same Treatment?
In recent years, CAR-T cell therapy (Chimeric Antigen Receptor T-cell Therapy) has become one of the most groundbreak...

China's Rapid Medical Innovation: What Opportunities Are Available to Access New Therapies?
In recent years, global medical innovation has entered a period of rapid growth. Breakthroughs in innovative medicine...

2026 ASCO: China’s Innovative Drug Boom — 12 Chinese Biopharma Companies and 13 Major Studies Enter the Global Spotlight
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2, 2026.

In-Depth Analysis

From Frequent Management to Long-Acting Treatment: How Plozasiran's Three-Month Dosing Is Changing FCS Care

Is Head and Neck Cancer Hereditary? A Comprehensive Guide to Genetics, Risk Factors, and Prevention Strategies

China's First Generic Tiotropium Bromide and Olodaterol Inhalation Spray Approved: Ending an 8-Year Market Exclusivity and Bringing New Options for COPD Treatment

How Effective Is Afatinib for Head and Neck Cancer? Indications, Clinical Efficacy, and Safety Overview